Diaceutics PLC Diaceutics PLC -- Directorate Changes (2604N)
September 21 2023 - 9:37AM
UK Regulatory
TIDMDXRX
RNS Number : 2604N
Diaceutics PLC
21 September 2023
Diaceutics PLC - Directorate Changes
Graham Paterson appointed as an independent Non-Executive
Director
Charles Hindson retiring as a Non-Executive Director
Belfast and London, 21 September 2023 - Diaceutics PLC (AIM:
DXRX) , a leading technology and solutions provider to the
pharmaceutical industry, today announces the appointment of Graham
Paterson as an independent Non-Executive Director of Diaceutics PLC
effective 1 October 2023. The Company also announces the retirement
of Charles Hindson as a Non-Executive Director of Diaceutics PLC
also effective 1 October 2023.
Graham Paterson is a highly experienced business leader and
Non-Executive Director. He is currently a Non-Executive Director of
Invesco Perpetual UK Smaller Companies Investment Trust plc,
Baillie Gifford US Growth Trust plc and Chairman of Mobeus Income
and Growth 4 VCT plc. He has held senior executive roles in a
number of companies including TopQ Software Ltd and SL Capital
Partners.
Graham Paterson is a Chartered Accountant and a member of the
Institute of Chartered Accountants of Scotland and holds an Honours
degree in Economics and Management from the University of St.
Andrews. On appointment, Graham Paterson will become Chair of the
Audit and Remuneration Committees of Diaceutics PLC.
Deborah Davis, Diaceutics' Non-Executive Chair, commented: "I
would like to thank Charles for his hard work, dedication and much
valued counsel during the past four years and wish him well in his
future endeavours.
I warmly welcome Graham to the board of Diaceutics, his
extensive leadership and board experience will contribute
significantly to our work and support our growth as we become the
primary commercialisation partner for pharma and biotech companies
launching precision medicines."
Information required to be disclosed pursuant to Schedule Two,
paragraph (g) of the AIM Rules for Companies:
The following information is disclosed in relation to Graham
Douglas Paterson, aged 52:
Current Directorships Past Directorships (previous
5 years)
Baillie Gifford US Growth The IDco Ltd
Trust Plc
Octopus VCT 4 Plc
Invesco Perpetual UK Smaller
Companies Investment Trust Berry Starquest Limited
Plc
Mobeus Income and Growth
4 VCT Plc
Datactics Ltd
Substantive Research Ltd
The Wemyss Development Company
Ltd
GDP 1 Ltd
-----------------------------
Graham Paterson does not hold any ordinary shares or share
options in the Company.
Save for the information disclosed above, there is no other
information to be disclosed under Schedule 2(g) of the AIM
Rules.
Enquiries:
Diaceutics PLC Tel: +44 (0)28 9040 6500
Peter Keeling, Chief Executive Officer investorrelations@diaceutics.com
Ryan Keeling, Chief Innovation Officer
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0)20 7710 7600
& Broker)
Ben Maddison
Nick Harland
Kate Hanshaw
Alma PR Tel: +44 (0)20 3405 0205
Caroline Forde diaceutics@almapr.co.uk
Matthew Young
Kinvara Verdon
About Diaceutics
At Diaceutics we believe that every patient should get the
opportunity to receive the right test and the right therapy to
positively impact their disease outcome.
We provide the world's leading pharma and biotech companies with
an end-to-end commercialization solution for precision medicines
through data analytics, scientific and advisory services enabled by
our platform DXRX - The Diagnostic Network(R).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOALBMJTMTJTBJJ
(END) Dow Jones Newswires
September 21, 2023 09:37 ET (13:37 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2024 to Jun 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Jun 2023 to Jun 2024